Accumulus Technologies has introduced the Accumulus Connector.

      The startup, which emerged from the nonprofit Accumulus Synergy last August, has established a network linking pharmaceutical and biotech firms to regulators in over 70 countries. The newly launched Connector allows access to this network without requiring companies to abandon their existing systems.

      Gaining drug approval in multiple countries at once necessitates submitting identical information to various national regulatory agencies, each with unique systems, formats, and timelines. For most companies in the pharmaceutical and biotech sectors, this process involves tedious manual reconciliation of internal systems, considerable duplication of effort, and a submission schedule that often exceeds what the scientific basis would typically indicate.

      San Francisco-based SaaS company Accumulus Technologies, which spun out from the regulatory-tech nonprofit Accumulus Synergy last August, has been developing a cloud platform aimed at alleviating this bottleneck. Today, it introduced the Accumulus Connector, a feature designed to provide direct access to the platform from within the systems that companies already utilize.

      The essence of Accumulus Technologies’ offering lies in its regulatory network, which is an active platform linked to over 70 national regulatory authorities, increasing from the 60-plus countries it covered at the time of the August 2025 spinout. Drug and biotech companies utilize this platform to manage concurrent submissions across different jurisdictions, facilitating what the industry refers to as “reliance pathways.” These pathways enable regulators in one country to use the review work of regulators in another, thereby accelerating the time it takes for a therapy to reach patients in markets that may otherwise be less prioritized.

      An illustrative case is the one involving Sanofi, announced in November 2024, which showcased the practical application of the platform when it was still part of Accumulus Synergy. This example highlighted how multi-regulator submissions could be managed simultaneously through a single interface rather than needing individual coordination across various jurisdictions.

      The Connector introduces a new integration layer to this network. Previously, companies had to engage directly with the Accumulus platform, and data would be exchanged between it and their own record systems through either manual reconciliation or custom integrations. The Connector allows the network to be accessed directly from those existing systems, such as ERP platforms, regulatory information management systems, and document management tools, facilitating real-time, bi-directional data flows between them and the regulatory network.

      Chanille Juneau, Chief Product and Technology Officer, noted that the design intention was to accommodate organizations “where they are,” without necessitating a move away from established infrastructure. The Connector is available to current subscribers of the Accumulus platform.

      The company is also envisioning this integration layer as functioning both ways: not only are pharma companies linking their systems to regulators, but regulators are also linking their systems to the Accumulus platform, fostering what they label a “bi-directional network across industry and authorities.”

      Accumulus Technologies is still a relatively new commercial entity, having formally separated from Accumulus Synergy only eight months ago. However, the platform it commercializes launched in February 2024, and the underlying nonprofit had been developing the ecosystem for several years prior, supported by founding sponsors from major global pharmaceutical companies. Francisco Nogueira, who developed the platform while at Accumulus Synergy, serves as CEO. The launch of the Connector marks the company’s first significant platform capability announcement since the spinout and underscores the inherent challenge in its commercial model: selling SaaS infrastructure to an industry that is fundamentally conservative, heavily regulated, and has historically treated data exchange between companies and regulators as a sensitive area, thereby necessitating a nonprofit intermediary to establish the trust required.